1naresh
Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) ) 1nareshArray ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) )T1, T2, PD values, and VMY determined via quantitative synthetic MRI pre- and postadministration of gadolinium-based contrast agenta
VMY (%) T1 (ms) T2 (ms) PD (%) With metastases pre-GBCA 21.14 ± 1.83 1061.68 ± 59.80 99.26 ± 12.37 75.90 ± 1.99 With metastases post-GBCA 21.92 ± 1.67 1010.35 ± 54.57 95.59 ± 13.75 74.85 ± 2.02 Difference 0.78 ± 0.85b −51.34 ± 43.44b −2.67 ± 9.35c −1.05 ± 1.26b Without metastases pre-GBCA 20.84 ± 1.08 1076.41 ± 75.40 98.43 ± 13.42 75.87 ± 1.79 Without metastases post-GBCA 21.59 ± 1.01 1029.58 ± 70.97 93.73 ± 15.39 74.59 ± 2.03 Difference 0.75 ± 0.53d −46.84 ± 31.23d −4.70 ± 12.21b −1.28 ± 1.35b